Budigalimab (Anti-PDCD1 / PD-1 / CD279)
Budigalimab (Anti-PDCD1 / PD-1 / CD279) (A3028-GRP)
Products
Description
Budigalimab (Anti-PDCD1 / PD-1 / CD279) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. It can be used in the treatment of advanced solid tumors. MW :145.84 KD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A3028 |